Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
19 Oktober 2009 - 10:20PM
PR Newswire (US)
EMERYVILLE, Calif., Oct. 19 /PRNewswire-FirstCall/ --
Neurobiological Technologies, Inc. (NASDAQ:NTII) ("NTI") announced
today it has submitted written notice to the NASDAQ Stock Market
LLC ("NASDAQ") that NTI intends to file a Form 25 with the
Securities and Exchange Commission ("SEC") on or about October 28,
2009 to effect the voluntary delisting of its common stock from
NASDAQ, if NTI's stockholders approve the dissolution of the
company pursuant to a Plan of Complete Liquidation and Dissolution
at the special meeting of stockholders planned for Tuesday, October
27, 2009. Details of NTI's plans to pay an extraordinary dividend,
delist its common stock from the Nasdaq Capital Market, discontinue
recording transfers of stock, cease its reporting obligations under
the Securities Exchange Act of 1934, as amended, and distribute its
net cash to stockholders can be found in a definitive proxy
statement filed with the SEC on September 22, 2009. About
Neurobiological Technologies, Inc. Neurobiological Technologies,
Inc. is a biopharmaceutical company historically focused on
developing investigational drugs for central nervous system
conditions. DATASOURCE: Neurobiological Technologies, Inc. CONTACT:
Matthew M. Loar, CFO of Neurobiological Technologies, Inc.,
+1-510-595-6000 Web Site: http://www.ntii.com/
Copyright